Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

mulative platelet and neutrophil toxicity and mild diarrhea. Grade 1 neuropathy was observed in three patients, and no neuropathy higher than grade 1 was observed in any patients, including four patients who have received a cumulative dose >900 mg/m2. Transient grade 3-4 neutrophil toxicity occurred in 32 percent of patients and platelet toxicity in 13 percent of patients. Hematologic toxicity was more frequent in the every-two- week schedule. In the every-four-week schedule, no dose-limiting toxicity has been observed with doses of picoplatin up to 180 mg/m2. Picoplatin was administered at doses up to 90 mg/m2 every two weeks and 180 mg/m2 every four weeks. Both the biweekly and monthly regimens are still being evaluated to define their respective maximum tolerated doses.

Phase 1 HRPC Trial Data

The Phase 1 component of the HRPC trial is being conducted in patients with metastatic disease who had not previously been treated with chemotherapy. Study participants received either docetaxel 60 mg/m2 every three weeks plus prednisone 5 mg twice daily plus picoplatin or docetaxel 75 mg/m2 every three weeks plus prednisone 5 mg twice daily plus picoplatin. Picoplatin was given to sequential cohorts of subjects at 60, 80, 100 and 120 mg/m2 with docetaxel 60 mg/m2 and at 100 and 120 mg/m2 with docetaxel 75 mg/m2.

To date, 26 patients have been treated; four patients have completed 10 cycles of therapy and 15 patients remain on treatment. Therapy has been well tolerated, with transient grade 3-4 neutropenia occurring in 46 percent of patients and grade 3-4 thrombocytopenia in 8 percent of patients. Dose- limiting toxicity (grade 4 neutropenia) has been observed at 120 mg/m2 when given with 60 mg/m2 docetaxel. Dose reduction for persistent hematologic toxicity has been infrequent for doses less than 120 mg/m2 picoplatin, and there has been no cumulative myelotoxicity. Dose escalation continues with picoplatin with docetaxel at 75 mg/m2.

Planned Pha
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ... Closures - Global Strategic Business Report" report to their ... the US, Canada , Japan ... , Latin America , and Rest ... for Surgical Incision Closures in US$ Million by the following ...
(Date:6/2/2015)... BOSTON , June 2, 2015 ... an additional $75 million from its recently announced synthetic ... raised to $300 million. Investors have purchased Convertible Limited ... quarterly payments equal to 2.0% of any future global ... or are fully paid. Investors also have the option, ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Surgical Incision Closures - Global Strategic Business Report 2015 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 DailyEndorphin is ... "events" programming module. With this highly configurable new ... and report on many components of its wellness programming ... no additional charge. , With this new module, annual ... DE challenges, (2) Create participant surveys, (3) Continually report ...
(Date:6/3/2015)... “ Scanalytics ” was featured on NewsWatch as part ... and coolest technology products available to consumers. Andrew Tropeano, ... the review and shared with viewers how this technology ... , Tracking statistics in business is invaluable in analyzing ... this goes a step beyond revenue statistics and tracking ...
(Date:6/3/2015)... Fit Body Boot Camp is America’s fastest ... helps thousands of individuals across the country lose weight and ... the gym and get the fitness results they want the ... out any gym membership: , Tip #1 – Don’t do ... is saying motivated and on track. Attempting to overcome these ...
(Date:6/3/2015)... 2015 Come on out in support ... 200-mile overnight relay beginning in Madison, Wisconsin on Friday, ... June 13th. , For the 4th consecutive year, a ... run to raise money for the Brain Aneurysm Foundation. ... of the Neurosurgery staff from The University of Illinois ...
(Date:6/3/2015)... June 03, 2015 Unfortunately, a majority of ... comes to providing comfort to the users throughout the year. ... or one from the local market, the makers generally tend ... in the process, often overlook comfort and health. To counter ... shoe, the creative heads at Vay Technologies have come up ...
Breaking Medicine News(10 mins):Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Technology to Analyze Foot Traffic in Retail Stores was featured on NewsWatch Television 2Health News:Summer Body Slim-Down: 5 Ways to Avoid Quitting Gym Memberships this Summer 2Health News:Summer Body Slim-Down: 5 Ways to Avoid Quitting Gym Memberships this Summer 3Health News:4th Annual Ragnar Relay from Madison, WI to Chicago, IL Once Again Benefits Renowned Brain Aneurysm Foundation 2Health News:Vay Technologies Launches uGALE the High Tech Insole Technology for Shoes on KickStarter 2Health News:Vay Technologies Launches uGALE the High Tech Insole Technology for Shoes on KickStarter 3
... St. Jude researchers identify a molecular mechanism ... MEMPHIS, Tenn., Aug. 11 St. Jude ... the molecular,mechanisms underlying the genetic brain malformation ... insights into the most,common developmental malformation of ...
... in 2Q08 -- ... -- -- 2Q08 Diluted ... YORK, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... development, manufacture and commercialization,of a broad range of prescription and ...
... $17.9 Million Treatment Tip and Other Consumables Revenue Up 15% ... ... Thermage, Inc.,(Nasdaq: THRM ), a leader in non-invasive tissue tightening in ... 30, 2008., Revenue for the second quarter of 2008 totaled $17.9 ...
... progenitors may provide context for tumor formation, new treatments ... Learning more about normal cells that give rise to ... cancer, according to Duke University Medical Center researchers who ... , "Identifying the specific, normal cells that cancer come ...
... finds , , MONDAY, Aug. 11 (HealthDay News) -- ... the 20/20 vision physicians consider optimal because they ... curve known as astigmatism, a large, new study ... eye-focus problems -- collectively known as "refractive errors"-- ...
... with fewer disabilities, study finds , , MONDAY, Aug. 11 (HealthDay ... death -- and even the creeping ravages of time -- ... has found that older runners live longer and suffer fewer ... apply to a variety of aerobic exercises, including walking, said ...
Cached Medicine News:Health News:New Insight Into Most Common Forebrain Malformation 2Health News:New Insight Into Most Common Forebrain Malformation 3Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 2Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 3Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 4Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 5Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 6Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 7Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 2Health News:Thermage Announces Second Quarter 2008 Financial Results 3Health News:Thermage Announces Second Quarter 2008 Financial Results 4Health News:Thermage Announces Second Quarter 2008 Financial Results 5Health News:Thermage Announces Second Quarter 2008 Financial Results 6Health News:Thermage Announces Second Quarter 2008 Financial Results 7Health News:Thermage Announces Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 9Health News:Researchers Hunt Normal Cells That Give Rise to Cancer 2Health News:Half of U.S. Adults Lack 20/20 Vision 2Health News:Half of U.S. Adults Lack 20/20 Vision 3Health News:Run for Your Life 2Health News:Run for Your Life 3
... Left Ventricular Assist System (LVAS) is a ... restore hemodynamic function and improve patient outcomes ... action of a single-moving part, the HeartMate ... support by pumping blood from the heart ...
... standard to extra-wide wheelchairs (18" to 43") ... heavy-duty, anodized aluminum weighing platform is equipped ... easy access for large patients. Weight is ... readout. The 6772 has the unique features ...
... Bariatric Stand-On Scale is designed to accommodate ... physicians scales only weigh up to 300 ... surface, or patients position on the scale., ... profile only 1 1/4 inches high. ...
... hormone (PTH) is synthesized by the ... response to decreased extracellular calcium concentrations. ... resorption and decreasing calcium excretion by ... circulation, intact PTH is rapidly degraded ...
Medicine Products: